Blood Glucose Monitoring Devices Market Outlook:
Blood Glucose Monitoring Devices Market size was valued at USD 21 billion in 2025 and is anticipated to reach USD 46.91 billion by the end of 2035, expanding at around 8.37% CAGR during the forecast period, i.e., between 2026-2035. In 2026, the industry size of blood glucose monitoring devices is evaluated at USD 22.76 billion.
The global blood glucose monitoring devices market is witnessing steady growth, driven by the increasing number of diabetes cases across the world. Some of the factors driving an exponential growth in diabetic patient pool includes lifestyle changes, rising obesity levels, and an aging population base, which require regular glucose monitoring and long-term disease management. Consequently, blood glucose monitoring has become an integral part of diabetes care across both medical and home-based settings.
The market is also benefiting from greater awareness of diabetes management and the importance of routine glucose testing in preventing disease complications. According to the International Diabetes Federation (IDF), approximately 589 million adults aged 20–79 years were living with diabetes globally, and this number is anticipated to reach 853 million by 2050. In addition, healthcare providers are supporting preventive care and ongoing disease management, and helping in the use of blood glucose monitoring solutions across diverse patient groups.
Key Blood Glucose Monitoring Devices Market Insights Summary:
Regional Highlights:
- North America is expected to command 40% of the global blood glucose monitoring devices market by 2035, underpinned by the growing diabetes patient population, favorable reimbursement policies, and increasing adoption of continuous glucose monitoring systems
- Asia Pacific is poised to witness the fastest expansion in the market through 2035, fueled by the rising prevalence of diabetes and increasing focus on diabetes management across China, India, and Japan
Segment Insights:
- The self-monitoring blood glucose (SMBG) devices segment of the blood glucose monitoring devices market is projected to capture 46.2% of market share by 2035, attributed to its affordability, widespread availability, and essential role in routine diabetes management
- The glucometer devices segment is forecast to hold 47.3% of the market by 2035, reinforced by the growing diabetic population, rising home-care adoption, and ongoing improvements in device convenience
Key Growth Trends:
- Growing adoption of CGM systems
- Expansion of home-based diabetes management
Major Challenges:
- High cost of CGM systems
- Accuracy limitations and calibration requirements
Key Players: Abbott Laboratories (U.S.), Dexcom, Inc. (U.S.), Medtronic plc (Ireland), F. Hoffmann-La Roche Ltd. (Switzerland), Ascensia Diabetes Care Holdings AG (Switzerland), LifeScan, Inc. (U.S.), Senseonics Holdings, Inc. (U.S.), Ypsomed Holding AG (Switzerland), B. Braun Melsungen AG (Germany), Terumo Corporation (Japan), Arkray, Inc. (Japan), Nipro Corporation (Japan), A. Menarini Diagnostics S.r.l. (Italy), Sinocare Inc. (China), i-SENS, Inc. (South Korea), AgaMatrix, Inc. (U.S.), Trividia Health, Inc. (U.S.), Nova Biomedical Corporation (U.S.), Sanofi S.A. (France).
Global Blood Glucose Monitoring Devices Market Forecast and Regional Outlook:
Market Size & Growth Projections:
- 2025 Market Size: USD 21 billion
- 2026 Market Size: USD 22.76 billion
- Projected Market Size: USD 46.91 billion by 2035
- Growth Forecasts: 8.37% CAGR (2026-2035)
Key Regional Dynamics:
- Largest Region: North America (40% share by 2035)
- Fastest Growing Region: Asia Pacific
- Dominating Countries: United States, China, Germany, Japan, Canada
- Emerging Countries: India, South Korea, Brazil, Saudi Arabia, Indonesia
Last updated on : 14 July, 2026
Blood Glucose Monitoring Devices Market - Growth Drivers and Challenges
Growth Drivers
- Growing adoption of CGM systems: The use of CGM devices has increased as they provide continuous reading throughout the day, which lessens the reliance on traditional methods like finger-prick testing. According to the American Diabetes Association (ADA), CGM is increasingly recommended as a standard component of diabetes management for individuals requiring intensive glucose monitoring. The increased use of this device in diabetes management in clinic, healthcare, and homecare settings has been supported by continuous glucose data. Product development such as sensors with longer wear durations, smaller designs, and smartphone compatibility devices, has also supported wider adoption of CGM systems. These devices are becoming a regular part of monitoring the pattern of diabetes in healthcare settings.
- Expansion of home-based diabetes management: The growing attention on remote patient monitoring and self- management as contributed to increased adoption of home-based glucose monitoring solutions. According to the January 2026 Centers for Disease Control and Prevention (CDC) data, approximately 40.1 million people in the United States are living with diabetes. The increasing number of patients who require ongoing disease management has supported the use of home-based glucose monitoring solutions and remote patient monitoring programs.
This has increased the use of blood glucose monitoring devices among individuals requiring ongoing disease management. The availability of connected and easy-to-use devices has further increased their use in homecare setting. Moreover, healthcare organizations are placing greater focus on long-term disease management and reducing unnecessary clinical visits. Accordingly, blood glucose monitoring devices are being used more often in home-based settings for patients requiring regular diabetes monitoring. - Increasing healthcare expenditure on diabetes care: Diabetes management requires considerable healthcare spending in several countries due to the growing number of patients who require long-term care and monitoring. According to the World Health Organization (WHO), diabetes is among the leading causes of healthcare expenditure globally, with countries continuing to increase investments in disease prevention, diagnosis, and management programs.
Healthcare providers, government agencies, and public health organizations continue to assign resources toward diabetes screening, monitoring, and treatment services. This has increased the use of glucose monitoring technologies across hospitals, clinics, and homecare settings. In several markets, government-led programs and healthcare investments have also improved access to the blood glucose monitoring devices. Moreover, the financial pressure associated with diabetes-related complications has encouraged greater attention toward regular glucose monitoring as part of routine disease management.
Challenges
- High cost of CGM systems: Along with the initial device purchase, CGM users are required to replace sensors and other consumable components frequently, which increases the overall cost associated with these systems. Compared with traditional self-monitoring blood glucose (SMBG) devices, CGM systems incur higher recurring costs, which can limit their use in cost-sensitive healthcare markets. Reimbursement coverage for CGM devices also remains limited in some countries, resulting in higher out-of-pocket spending for users. Although CGM systems are widely used in diabetes management, the cost of devices and replacement components remains a key factor influencing their use across several developing healthcare markets, including parts of Asia Pacific and Latin America.
- Accuracy limitations and calibration requirements: The accuracy of glucose reading may vary due to some factors, which include variation sensor, calibration requirement, and individual patient conditions. This is the reason why healthcare providers may continue to use additional blood glucose tests to confirm readings before making any treatment decisions. This can reduce dependency on advanced monitoring systems in certain medical cases. For manufacturers and healthcare providers maintaining consistent device performance and accuracy among different patient groups remains an important decision.
Blood Glucose Monitoring Devices Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2025 |
|
Forecast Period |
2026-2035 |
|
CAGR |
8.37% |
|
Base Year Market Size (2025) |
USD 21 billion |
|
Forecast Year Market Size (2035) |
USD 46.91 billion |
|
Regional Scope |
|
Blood Glucose Monitoring Devices Market Segmentation:
Type Segment Analysis
The self-monitoring blood glucose (SMBG) devices segment is anticipated to account the largest share for 46.2% of the market by the end of 2035. Across different healthcare market SMBG devices remain commonly used as a part of diabetes care due to their affordability and availability. For daily glucose monitoring blood glucose meters, test strips, and lancets are regularly used in hospitals, clinics, and in homecare settings. For patients who need regular monitoring, daily glucose testing plays a vital role of diabetes management. The global availability of SMBG products across different healthcare settings has helped maintain their use across a large patient population.
Component Segment Analysis
The glucometer devices segment is projected to hold a market share of 47.3% by around 2035. The rise in number of diabetes patients and their need for home-care settings have made glucometer devices in demand. Across different healthcare markets, their stable role in diabetes management, along with wider product availability, has supported consistent demand. Moreover, manufacturers continue to introduce glucometer improvements, making routine tests more convenient across healthcare and home-care settings. The continued use of this device globally will support the segment’s position throughout the forecast period.
End user Segment Analysis
The hospital sub- segment is anticipated to hold the highest market share of 36% by the end of 2035. The most important primary setting remains hospital, because of consistent blood glucose monitoring devices, diabetes diagnosis, treatment, and patient monitoring. The availability of advanced healthcare facilities and trained medical professionals has supported the use of glucose monitoring technologies across inpatient and outpatient care settings. However, the rising number of diabetes-related cases in hospital visits and regular glucose testing procedures continues to support product devices. Their role in managing critical patients which needed regular monitoring and specialized care, contributing to the segment's strong market position.
Our in-depth analysis of the blood glucose monitoring devices market includes the following segments:
|
Segment |
Subsegments |
|
Type |
|
|
Component |
|
|
End user |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Blood Glucose Monitoring Devices Market - Regional Analysis
North America Market Insights
North America holds the market share of 40% of the global blood glucose monitoring devices market anticipated by the end of 2035. According to CDC report 40.1 million people are living with diagnosed or un- diagnosed diabetes in America, highlighting the substantial demand for diabetes management and glucose monitoring solutions across North America. The regional market is led by United States and Canada, where they have an increasing number of diabetes patients and remain an early global adopter for glucose monitoring technologies. The presence of favorable repayment policies and increasing use of continuous glucose monitoring (CGM) systems has further supported market growth. In addition, the awareness regarding diabetes management and strong healthcare spending continue to contribute to the demand for blood glucose monitoring devices across the region.
The U.S. represents the largest market for blood glucose monitoring devices in North America. The country has a major population who have diabetes and has been the first market to adopt glucose monitoring technologies, including CGM systems. Across hospitals, clinics, and homecare settings, the blood glucose monitoring devices has increased because of the repay support and wider use of digital healthcare technologies. Moreover, healthcare providers are showing greater focus on regular diabetes monitoring and long-term disease management. There are recent developments in diabetes care and the presence of established manufacturers continue to support the market position of the country.
The Canada blood glucose monitoring devices market is witnessing stable growth, supported by increasing awareness regarding diabetes management and improved access to healthcare services. The use of glucose monitoring devices has increased among diabetic patients across the country. However, the healthcare providers are placing greater highlight on routine glucose monitoring and early intervention, contributing to the adoption of blood glucose monitoring technologies across the country.
Asia Pacific Market Insights
Asia Pacific is expected to record the fastest growth in the blood glucose monitoring devices market through 2035. The region is witnessing an increase in number of diabetes cases, which creates strong demand for glucose monitoring solutions. Some of the major markets within the region are supported by China, India and Japan, because of the larger diabetic population, and their increasing attention towards diabetes management.
According to the International Diabetes Federation (IDF), Western Pacific considered for approximately 215 million adults living with diabetes, while South East Asia accounted for approximately 107 million adults with diabetes in 2024, highlighting the substantial diabetes burden across Asia Pacific. The increase in market growth includes healthcare facilities, expenditure, and improving access to diabetes care services. The rise in awareness for routine glucose monitoring and more availability of advanced monitoring technologies have also encouraged wider adoption across several countries in the region.
The blood glucose monitoring device for Asia Pacific were China holds the largest market. The country has a major diabetic population, that result in strong demand for diabetes management solutions. According to the WHO, China has one of the world's largest populations affected by diabetes, making diabetes prevention, monitoring, and management a major public health priority. Improvements in healthcare services, increasing awareness regarding diabetes care, and wider availability of glucose monitoring technologies have supported the use of blood glucose monitoring devices across healthcare settings. The increasing adoption of CGM systems is also contributing to market growth in the country.
Japan continues to represent an important market place for blood glucose monitoring technologies because of its well-established healthcare system and their high focus on chronic disease management. The use of advanced glucose monitoring solutions has increased as healthcare providers continue to highlight regular diabetes monitoring and long-term patient care. The availability of modern healthcare facilities and high use of digital healthcare technologies further support demand for blood glucose monitoring devices across the country.
Due to the rising number of diabetes patient and growing awareness regarding disease management, India is seeing a rising demand for blood glucose monitoring device. India has approximately 101 million people living with diabetes and around 136 million people with prediabetes diagnosed. Healthcare providers are placing greater focus on routine glucose monitoring and early diabetes management, supporting the use of monitoring devices across hospitals, clinics, and homecare settings. In addition, improving healthcare access and increasing diabetes care initiatives continue to support the adoption of blood glucose monitoring technologies in the country.
Europe Market Insights
During the forecast period, Europe is expected to maintain a stable position in the blood glucose monitoring devices market. Countries such as Germany, the United Kingdom, and France continue to contribute considerably to the regional demand for blood glucose monitoring devices. The region continues to pay attention to early diagnosis, disease management, and preventive healthcare, supporting the use of glucose monitoring technologies. Several European countries have established healthcare systems that facilitate access to diabetes care and monitoring services.
Germany is expected to hold the largest blood glucose monitoring devices market in Europe by then end of 2035. According to the WHO , diabetes remains a major public health challenge across Europe, creating sustained demand for disease monitoring and management solutions. As healthcare providers continue to focus on regular diabetes management and long-term patient monitoring, the use of blood glucose monitoring technologies is expected to increase in the forthcoming years.
The UK blood glucose monitoring devices market is supported by paying attention toward diabetes management and preventive healthcare. According to Diabetes UK reports more than 4.7 million people in the UK are living with diabetes, highlighting the continued need for glucose monitoring and long-term disease management solutions. Across healthcare settings, as a part of long-term disease management, healthcare providers continue to encourage routine glucose monitoring. The blood glucose monitoring solutions are supported throughout the country because of the rising use of digital healthcare technologies and wider access to diabetes care services.
Key Blood Glucose Monitoring Devices Market Players:
- Abbott Laboratories (U.S.)
- Dexcom, Inc. (U.S.)
- Medtronic plc (Ireland)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Ascensia Diabetes Care Holdings AG (Switzerland)
- LifeScan, Inc. (U.S.)
- Senseonics Holdings, Inc. (U.S.)
- Ypsomed Holding AG (Switzerland)
- B. Braun Melsungen AG (Germany)
- Terumo Corporation (Japan)
- Arkray, Inc. (Japan)
- Nipro Corporation (Japan)
- A. Menarini Diagnostics S.r.l. (Italy)
- Sinocare Inc. (China)
- i-SENS, Inc. (South Korea)
- AgaMatrix, Inc. (U.S.)
- Trividia Health, Inc. (U.S.)
- Nova Biomedical Corporation (U.S.)
- Sanofi S.A. (France)/
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Abbott Laboratories is a leading manufacturer in the blood glucose monitoring devices market and has strengthened its position through continuous innovation in continuous glucose monitoring, offering user-friendly devices that support diabetes management in home and clinical settings. Its extensive global distribution network, strong research and development capabilities, and focus on digital health integration have enabled Abbott to expand its presence across developed and emerging markets, making it one of the industry's most influential participants.
- F. Hoffmann-La Roche Ltd. maintains a strong position in the market through its Accu-Chek product portfolio. The company offers blood glucose meters, test strips, lancing devices, and diabetes management software designed to improve patient outcomes. Its established global presence, strong clinical expertise, and collaborations with healthcare providers have enabled the company to remain a trusted manufacturer in both developed and emerging healthcare markets.
- Medtronic plc is a prominent player in the market, particularly through its advanced continuous glucose monitoring technologies integrated with insulin delivery systems. The company focuses on developing connected diabetes management solutions that enable real-time glucose monitoring and automated insulin administration.
- DexCom, Inc. is recognized as one of the leading innovators in continuous glucose monitoring technology. The company's CGM systems provide real-time glucose readings, predictive alerts, and seamless connectivity with smartphones and insulin delivery devices. Dexcom continues to strengthen its market position through technological advancements, product miniaturization, and integration with digital health platforms.
Here is a list of key players operating in the global market:
The market players are keen on diversifying their product portfolio by streamlining R&D efforts and drive innovation. The rising diabetes crisis across the globe is prompting regional players to expand their foreign operations and establish their presence. They are also opting for strategic collaborations, partnerships, and mergers and acquisitions to capitalize on growing market opportunities.
Corporate Landscape of the Market
Recent Developments
- In February 2026, MiniMed, Medtronic plc's diabetes business, announced the launch of its initial public offering (IPO) roadshow as part of Medtronic's strategic plan to establish the diabetes business as an independent public company. The development highlights the growing importance of diabetes management technologies, including glucose monitoring systems and insulin delivery solutions, within the global healthcare sector.
- In July 2025, Dexcom launched its AI-powered Smart Food Logging feature across the Dexcom G7 and Stelo glucose biosensing platforms. The feature enables users to capture meal images, automatically identify food ingredients, and gain personalized insights into how meals impact glucose levels, supporting digital diabetes management and improving user engagement with continuous glucose monitoring technologies.
- In June 2024, Abbott Laboratories received U.S. FDA clearance for its over-the-counter continuous glucose monitoring systems, Lingo™ and Libre Rio™. The approval expanded access to glucose monitoring technologies for consumers and individuals with Type 2 diabetes who do not use insulin, further strengthening Abbott's position in the blood glucose monitoring devices market.
- Report ID: 4606
- Published Date: Jul 14, 2026
- Report Format: PDF, PPT
- Explore a preview of key market trends and insights
- Review sample data tables and segment breakdowns
- Experience the quality of our visual data representations
- Evaluate our report structure and research methodology
- Get a glimpse of competitive landscape analysis
- Understand how regional forecasts are presented
- Assess the depth of company profiling and benchmarking
- Preview how actionable insights can support your strategy
Explore real data and analysis
Frequently Asked Questions (FAQ)
About this Report
Connect with our Expert
Report, 2026-2035
Copyright @ 2026 Research Nester. All Rights Reserved.
